Sign in
CompletedPhase 2

A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Key facts

Who runs it
Changchun GeneScience Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
165 people enrolled
Started
20 Jul 2023
Ended
19 Jan 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Genakumab for injection
  • Colchicine
Record updated
1 January 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Other criteria

  • Signed written informed consent before any study procedure is performed
  • Male or female, 18 years ≤ age ≤ 75 years
  • BMI ≤ 40kg/m2
  • Confirmed diagnosis of gout meeting the American College of Rheumatology (ACR) 2015 preliminary criteria for the classification of arthritis of primary gout
  • History of ≥2 gout flare within 12 months prior to screening
  • Willingness to initiate urate-lowering therapy or having initiated urate-lowering therapy within 1 week prior to screening

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and efficacy of Genakumab in prevention of acute flares in gout patients initiating urate-lowering therapyurate-lowering

The 2 groups in the trial

  • Genakumab groupTreatment being tested

    Genakumab 100mg single injection、Genakumab 200mg single injection

    Treatment: Genakumab for injection

  • Colchicine groupExisting treatment, for comparison

    Oral colchicine 0.5mg once a day for 12 weeks

    Treatment: Colchicine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering
Record updated
1 January 2025